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Sudden	Gains		2		1	 SUDDEN	GAINS	IN	ANOREXIA	NERVOSA	2	
Abstract	3	
Objective:	Sudden	gains	(SGs),	broadly	defined	as	sudden	symptom	reductions	4	 occurring	between	two	consecutive	treatment	sessions,	have	been	associated	with	5	 improved	treatment	outcomes	in	anxiety	and	depression.	The	present	study	is	the	first	6	 to	formally	define	SGs	in	anorexia	nervosa	and	explore	the	characteristics,	demographic	7	 and	baseline	clinical	predictors,	and	clinical	impact	of	SGs	in	anorexia	nervosa.	Method:	8	 This	is	a	secondary	analysis	of	data	from	89	outpatients	with	broadly	defined	anorexia	9	 nervosa	who	received	one	of	two	psychotherapeutic	interventions	as	part	of	the	10	 MOSAIC	trial	(Schmidt	et	al.,	2015).	SGs	were	defined	using	session-by-session	Body	11	 Mass	Index	(BMI)	measures.	This	study	investigated	whether	SGs	were	associated	with	12	 changes	in	BMI,	eating	disorder	symptomology,	general	psychopathology,	and	13	 psychosocial	impairment	between	baseline	and	6,	12	and	24	months	follow-up.	Results:	14	 SGs,	experienced	by	61.8%	of	patients,	mostly	occurred	during	the	early	and	middle	15	 phases	of	treatment.	A	larger	proportion	of	SGs	predicted	larger	increases	in	BMI	16	 between	baseline	and	6,	12	and	24	months	follow-up.	Amongst	those	experiencing	at	17	 least	one	SG,	fewer	days	between	baseline	and	a	patient’s	first	SG	predicted	a	larger	18	 increase	in	BMI	between	baseline	and	both	6	and	12	months	follow-up.	The	proportion	19	 and	timing	of	SGs	did	not	predict	changes	in	other	outcome	measures.	Discussion:	SGs	20	 in	BMI	during	the	outpatient	treatment	of	anorexia	nervosa	are	clinically	useful	21	 predictors	of	longer-term	weight	outcomes.		22	
	23	
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Sudden	Gains	in	the	Outpatient	Treatment	of	Anorexia	Nervosa:	A	Process-1	
Outcome	Study	2	 Anorexia	Nervosa	(AN)	is	associated	with	high	disability	and	mortality,	posing	major	3	 psychological	and	economic	burden	(Gatt	et	al.,	2014;	Stuhldreher	et	al.,	2012).	4	 International	treatment	guidelines	recommend	psychotherapy	for	adults	with	AN	5	 (National	Collaborating	Centre	for	Mental	Health.,	2004)	and	high	quality	large	scale	6	 randomized	controlled	trials	(RCTs)	are	now	beginning	to	emerge	(Treasure	et	al.,	7	 2015;	Zipfel,	Giel,	Bulik,	Hay,	&	Schmidt,	2015).		8	 	 In	RCTs,	treatment	outcomes	are	compared	after	the	end	of	treatment	on	a	group	9	 level,	an	approach,	which	largely	ignores	outcome	variation	between	individuals	10	 (Collins	&	Sayer,	2000).	However,	there	has	been	a	greater	emerging	interest	in	the	11	 processes	of	change	in	Anorexia	Nervosa,	with	researchers	finding	that	factors	relating	12	 to	how	patients	process	and	use	treatment	between	sessions	is	related	to	treatment	13	 outcomes	(Hartmann	et	al.,	2016;	Zeeck	et	al.,	2016).	It	may	be	further	argued	that	14	 focusing	on	the	processes	of	change	will	help	to	determine	when	the	majority	of	15	 symptom	change	is	taking	place	(Kazdin	&	Nock,	2003).	Analyzing	the	content	of	16	 therapeutic	sessions	prior	to	this	symptom	change	may	enable	researchers	to	identify	17	 which	components	of	therapy	are	most	important	in	affecting	longer-term	symptom	18	 change.		19	 One	characteristic	of	the	therapeutic	process	is	sudden	gains	(SGs);	defined	as	20	 sudden	reductions	in	symptoms	between	two	consecutive	treatment	sessions.	SGs	were	21	 first	introduced	by	Tang	and	DeRubeis	(1999)	in	the	context	of	Cognitive	Behavioral	22	 Therapy	(CBT)	for	depression,	who	argued	that	SGs	should	be	large	(a)	in	absolute	23	 terms,	(b)	relative	to	symptom	severity	before	the	gain,	and	(c)	relative	to	symptom	24	 fluctuation	preceding	and	following	the	gain.	They	defined	SGs	using	scores	on	the	Beck	25	
		
Sudden	Gains		4	Depression	Inventory	(BDI;	Beck	&	Steer,	1987):	1	 “A	sudden	gain	occurred	between	session	N	and	session	N	+	1	if	(a)	the	gain	was	2	 at	least	7	BDI	points	(BDIN	–	BDIN+1	≥	7);	(b)	the	gain	represented	at	least	25%	of	3	 the	pregain	session’s	BDI	score	(BDIN	–	BDIN+1	≥	0.25	x	BDIN),	and	(c)	the	mean	4	 BDI	score	of	the	three	therapy	sessions	before	the	gain	(sessions	N	–	2,	N	–	1,	and	5	
N)	was	significantly	higher	than	the	mean	BDI	score	of	the	three	therapy	6	 sessions	after	the	gain	(sessions	N	+	1,	N	+	2,	and	N	+	3)	using	a	two-sample	t	test	7	 with	alpha	of	.05.”	(Tang	&	DeRubeis,	1999)		8	 More	than	50%	of	treatment	responders	experienced	SGs	during	treatment	(Tang	&	9	 DeRubeis,	1999)	and	those	who	experienced	SGs	were	less	depressed	at	post-treatment	10	 and	18-month	follow-up	compared	to	those	who	did	not.		11	 The	original	definition	has	been	criticized	and	altered	(Hardy	et	al.,	2005).	The	12	 ‘absolute	magnitude’	criterion	has	been	criticized	for	being	arbitrary	(Hofmann,	Schulz,	13	 Meuret,	Moscovitch,	&	Suvak,	2006);	the	‘relative	magnitude’	criterion	has	been	14	 criticized	for	assuming	that	symptom	measures	are	ratio	scales	(Utzinger,	Goldschmidt,	15	 Crosby,	Peterson,	&	Wonderlich,	2016)	and	has	been	found	to	have	minimal	impact	on	16	 SG	selection	(Tang,	DeRubeis,	Beberman,	&	Pham,	2005);	and	the	‘stability’	criterion	has	17	 been	criticized	for	precluding	examination	of	gains	between	the	first	and	second	18	 treatment	sessions	(Aderka,	Nickerson,	Bøe,	&	Hofmann,	2012).	However,	despite	19	 variations	in	definitions,	SGs	have	been	consistently	associated	with	better	treatment	20	 outcomes	(Aderka	et	al.,	2012).		21	 The	majority	of	studies	on	SGs	have	focused	on	anxiety	and	depression.	Only	one	22	 study	has	assessed	the	role	of	SGs	in	eating	disorders,	measured	using	the	Change	in	23	 Eating	Disorder	Symptoms	Scale	(CHEDS;	Spangler,	2010),	in	cognitive	behavioral	24	 therapy	for	bulimic	eating	disorders.	SGs	were	defined	using	two	criteria:	the	‘absolute	25	
		
Sudden	Gains		5	magnitude	criterion	required	a	decrease	of	at	least	12	points	on	the	CHEDS,	and	the	1	 ‘stability	criterion’	was	based	on	that	originally	used	by	Tang	and	DeRubeis	(1999).	2	 Over	50%	of	participants	had	at	least	one	SG,	and	those	experiencing	SGs	had	better	3	 CHEDS	outcome	scores	post-treatment	(Cavallini	&	Spangler,	2013).	To	date,	no	study	4	 has	assessed	whether	SGs	occur	in	patients	with	AN	during	treatment,	and,	if	so,	5	 whether	these	are	related	to	treatment	outcomes.		6	 There	is	also	debate	regarding	the	importance	of	the	timing	of	SGs.	Tang	and	7	 DeRubeis	(1999)	found	that	SGs	typically	occurred	early,	around	session	5,	and	there	is	8	 some	evidence	to	suggest	that	SGs	early	in	treatment	are	more	relevant	to	treatment	9	 outcomes	(Lutz,	Bachmann,	Tschitsaz,	Smart,	&	Lambert,	2007;	Stiles	et	al.,	2003).	10	 However,	there	is	considerable	variation	in	the	definition	of	what	constitutes	‘early’.	11	 Furthermore,	in	a	large	meta-analysis,	Aderka	et	al.	(2012)	found	no	significant	12	 differences	in	outcomes	between	those	who	experienced	SGs	early	vs.	later	in	13	 treatment.		14	 Although	SGs	have	been	associated	with	better	outcomes	post-treatment,	this	is	15	 not	always	maintained	at	longer-term	follow-up	(Clerkin,	Teachman,	&	Smith-Janik,	16	 2009).	In	addition,	SGs	are	often	only	associated	with	improvements	in	the	primary	17	 outcome	measure,	which	is	typically	the	same	measure	used	to	define	SGs	(Aderka	et	al.,	18	 2012).	This	may	be	due	to	definitions	of	SGs	being	too	lenient,	such	that	individuals	who	19	 experience	SGs	are	simply	those	who	improve	on	the	target	measure	during	treatment.	20	 Additional	criteria	may	therefore	be	required	in	order	to	ensure	that		SGs	are	truly	21	 sudden	and	are	measuring	more	than	simply	symptom	change	during	treatment.	22	 There	has	been	considerable	debate	regarding	how	SGs	should	be	defined	and	23	 measured	in	the	context	of	AN	(Utzinger	et	al.,	2016).	The	current	study	therefore	aimed	24	 to	operationalize	SGs,	using	data	from	a	clinical	trial	of	AN.	We	based	our	criteria	on	25	
		
Sudden	Gains		6	those	proposed	by	Tang	and	DeRubeis	(1999),	adding	an	additional	criterion	of	1	 ‘suddenness’.	We	aimed	to	explore	whether	there	are	SGs	in	BMI	during	treatment	of	2	 AN;	describe	the	characteristics	of	SGs,	including	their	frequency,	magnitude	and	3	 timing;	and	determine	whether	the	proportion	and	timing	of	SGs	predicts	outcomes	at	4	 6,	12	and	24	months	follow-up.	We	also	aimed	to	determine	whether	baseline	variables	5	 (including	demographic	and	clinical	characteristics)	differed	between	those	who	did	6	 and	did	not	experience	SGs	during	treatment.			7	 	8	 METHODS	9	 Data	Source	10	 The	current	study	used	data	from	The	Maudsley	Outpatient	Study	of	Treatments	for	11	 Anorexia	Nervosa	and	Related	Conditions	(MOSAIC;	Schmidt	et	al.,	2015),	and	this	trial’s	12	 2-year	follow-up	(Schmidt	et	al.,	2016);	a	large	multicenter,	two-arm	superiority	RCT	of	13	 adult	outpatients	with	broadly	defined	AN.	Patients	were	randomized	to	receive	one	of	14	 two	treatments:	the	Maudsley	Model	of	Anorexia	Nervosa	Treatment	for	Adults	15	 (MANTRA),	an	empirically	based	cognitive-interpersonal	manualized	treatment	16	 targeting	factors	thought	to	maintain	symptoms	of	AN	(Schmidt	&	Treasure,	2006;	17	 Treasure	&	Schmidt,	2013);	or	Specialist	Supportive	Clinical	Management	(SSCM),	a	18	 manualized	treatment,	which	involves	providing	information,	advice,	and	19	 encouragement	in	a	supportive	therapeutic	manner	(McIntosh	et	al.,	2006).	All	20	 participants	were	offered	at	least	20	individual	therapy	sessions	(patients	with	a	BMI	≤	21	 15kg/m2	were	offered	30	individual	sessions),	4	monthly	follow-up	sessions,	and	2	22	 additional	sessions	with	a	close	other.	Ethical	approval	for	the	trial	was	obtained	from	23	 the	Central	London	Research	Ethics	Committee	(REC)	4,	Royal	Free	Hospital,	London,	24	 National	Health	Service;	REC	Reference:	10/H0714/9.	Full	details	of	this	trial	are	25	
		
Sudden	Gains		7	available	elsewhere	(Schmidt	et	al.,	2013,	2015,	2016).		1	
Participants	2	 MOSAIC	participants	were	recruited	from	four	outpatient	ED	services	in	the	United	3	 Kingdom.	Information	regarding	inclusion/exclusion	criteria	and	participant	flow	4	 through	the	MOSAIC	trial	is	available	elsewhere	(Schmidt	et	al.,	2015,	2016).	Exclusion	5	 criteria	for	this	study	were	having	fewer	than	4	weight	measurements	and	no	height	6	 measurement.	Information	regarding	availability	of	weight	data	is	presented	in	figure	1.	7	 As	can	be	seen	from	figure	1,	almost	30%	of	MOSAIC	patient	files	were	missing.	This	is	8	 due	to	factors	such	as	patients	failing	to	start	treatment	(n=10),	files	being	lost,	and	9	 therapist	non-compliance	with	record	keeping,	with	two	therapists	accounting	for	10	10	 missing	files.	Comparisons	of	demographic	and	clinical	characteristics	of	missing	11	 MOSAIC	patients	and	the	present	subsample	are	presented	in	table	1,	indicating	12	 minimal	differences	between	these	two	subsamples.		13	 	14	 Outcome	Measures	15	 The	primary	outcome	in	the	MOSAIC	trial	was	BMI	(kg/m2).	Other	secondary	outcome	16	 measures	included:	ED	psychopathology,	measured	using	the	Eating	Disorders	17	 Examination	(EDE)	Interview	(Fairburn,	Cooper,	&	O’Connor,	2008),	or	the	18	 questionnaire	form	of	this	assessment	(EDE-Q);	general	psychopathology,	measured	19	 using	the	Depression,	Anxiety	and	Stress	Scale-21(DASS-21;	(Lovibond	&	Lovibond,	20	 1995));	obsessive-compulsive	symptomatology,	measured	using	the	Obsessive	21	 Compulsive	Inventory-Revised	(OCI-R;	(Foa	et	al.,	2002));	and	psychosocial	impairment,	22	 measured	using	the	Clinical	Impairment	Assessment	(CIA;	Bohn	&	Fairburn,	2008).	23	 Information	regarding	reliability	and	validity	of	these	measures	can	be	found	elsewhere	24	
		
Sudden	Gains		8	(see	Schmidt	et	al.,	2015).	EDE	and	EDE-Q	data	in	the	MOSAIC	trial	were	combined	into	1	 a	single	EDE	outcome	measure.	BMI	and	EDE	was	measured	at	baseline	and	6,	12	ad	24	2	 months	follow-up.	All	other	outcomes	were	measured	at	baseline	and	24	months	3	 follow-up.	4	 	5	 Procedure	6	 Session-by-session	weight	measures	were	extracted	from	patients’	files.	Weight	7	 measures	taken	more	than	365	days	after	baseline	(n=84)	were	excluded	to	ensure	that	8	 SGs	were	not	measured	after	the	12-month	follow-up.	The	researchers	recorded	the	9	 session	at	which	each	weight	measure	was	taken	and	the	number	of	days	between	10	 baseline	and	each	session.	All	other	data	(demographic	characteristics,	clinical	details,	11	 and	outcome	measures	described	above)	were	extracted	from	MOSAIC	trial	databases.	12	 	13	 Defining	Sudden	Gains		14	 Weight	measures	were	transformed	into	BMI	(weight/height)2.	SGs	were	measured	in	15	 terms	of	change	in	BMI	between	one	treatment	session	(pre-gain	session,	N)	and	the	16	 following	session	(post-gain	session,	N+1).	Meeting	the	criterion	of	absolute	magnitude	17	 required	an	average	between-session	increase	of	≥0.183kg/m2	per	week.	This	criterion	18	 is	based	on	the	NICE	guidelines’	recommendation	of	an	average	weight	gain	of	0.5kg	19	 /week	for	adults	with	anorexia	nervosa	treated	in	outpatient	settings	(National	20	 Collaborating	Centre	for	Mental	Health,	2004),	and	was	calculated	using	the	mean	21	 height	of	our	sample.	Although	it	may	be	argued	that	a	weight	gain	expected	to	be	the	22	 norm	within	the	NICE	guidelines	is	not	‘large’,	the	mean	weight	gain	during	treatment	23	 for	AN	is	much	lower	than	this	recommended	amount	(Hartmann,	Weber,	Herpertz,	24	 Zeeck	&	German	Treatment	Guideline	Group	for	Anorexia	N.,	2011).	Expecting	a	weight	25	
		
Sudden	Gains		9	gain	of	more	than	this	amount	may	therefore	be	considered	unrealistic.	The	second	1	 criterion	of	relative	magnitude	was	dropped,	as	it	has	been	shown	to	have	minimal	2	 impact	on	SG	selection	(Tang	et	al.,	2005).	Meeting	the	third	criterion	of	stability	3	 required	the	mean	BMI	of	the	three	measures	taken	during	sessions	N-2,	N-1	and	N	to	4	 be	significantly	lower	than	the	mean	BMI	of	sessions	N+1,	N+2	and	N+3,	as	calculated	5	 using	an	independent	samples	t-test	(α	=	0.05).	To	maximize	data	inclusion	for	SG	6	 calculation,	when	BMI	gains	occurred	between	sessions	where	there	were	two	pre-gain	7	 and/or	two	post-gain	measures,	t-tests	were	calculated	using	these	values.	Finally,	we	8	 added	an	additional	criterion	of	‘suddenness’,	which	required	the	rate	of	BMI	increase	9	 between	sessions	N	and	N+1	to	be	≥1.5	times	the	rate	of	BMI	change	between	sessions	10	 N-1	and	N.	11	 Due	to	considerable	variation	in	the	number	of	weight	measures	per	participant,	12	 the	proportion	of	SGs	was	calculated	by	dividing	patients’	total	number	of	SGs	by	that	13	 patients’	maximum	possible	number	of	SGs	(i.e.	total	number	of	weight	measure	–	3).	14	
	15	 Statistical	Analysis	16	 To	identify	baseline	characteristics	associated	with	SGs,	participants	were	split	into	17	 those	who	did	and	did	not	experience	SGs.	Independent	samples	t-tests	or	chi-squared	18	 tests	were	used	to	compare	demographic	characteristics	and	baseline	clinical	details	of	19	 the	two	groups.	Nonparametric	tests	were	used	where	appropriate.	20	 Multiple	linear	regression	analyses	were	used	to	investigate	whether	the	21	 proportion	of	SGs	predicted	better	long-term	outcomes.	Outcome	measures	included	22	 the	difference	in	BMI	and	EDE	scores	between	baseline	and	6,	12	and	24	months	post-23	 randomization,	and	the	difference	in	DASS-21,	OCI-R,	and	CIA	scores	between	baseline	24	 and	24	months	post-randomization.	In	order	to	maximize	statistical	power,	data	were	25	
		
Sudden	Gains		10	combined	across	treatment	arms.	In	doing	this,	we	are	assuming	that	any	associations	1	 between	the	proportion	and	timing	of	SGs	and	long-term	treatment	outcomes	are	not	2	 dependent	on	the	type	of	therapy.	Baseline	measures	of	bingeing,	vomiting	and	laxative	3	 use	were	included	as	confounders	due	to	the	effects	of	these	variables	on	weight,	for	4	 example	due	to	water	retention	(Rigaud,	Boulier,	Tallonneau,	Brindisi,	&	Rozen,	2010).	5	 Finally,	although	not	found	to	have	significant	effects	on	the	outcome	in	the	primary	6	 trial	analyses	(Schmidt	et	al.,	2015,	2016)	treatment	effects	were	also	allowed	for	by	7	 adding	treatment	group	into	the	regression	model.	8	 To	determine	whether	the	timing	of	the	first	SG	predicts	treatment	outcomes,	9	 regression	analyses	were	repeated	for	just	those	individuals	experiencing	SGs,	with	the	10	 independent	variable:	number	of	days	between	randomization	and	the	first	SG.		11	 	12	 RESULTS		13	 Describing	Sudden	Gains		14	 A	total	of	1697	treatment	sessions	were	analyzed	for	the	identification	of	SGs	across	all	15	 participants,	creating	1607	between-session	comparisons.	Within	our	final	sample,	the	16	 median	number	of	weight	measurements	was	20	(range	=	4	to	35),	and	the	median	17	 length	of	time	between	measures	was	7	days	(range	=	3	to	140).	18	 There	were	327	between-session	comparisons	meeting	the	‘absolute	magnitude’	19	 criterion,	122	of	which	also	met	the	‘stability’	criterion.	Adding	the	criterion	of	20	 ‘suddenness’	left	102	SGs	amongst	55	participants.	Thus,	61.8%	of	all	participants	21	 experienced	at	least	1	SG	in	BMI	during	therapy.			22	 We	examined	the	length,	frequency,	magnitude	and	timing	of	SGs	during	both	23	 treatments.	The	median	number	of	days	between	pregain	and	postgain	weight	24	 measures	was	7	(range	=	5	to	49)	for	both	treatments.	The	median	number	of	SGs	25	
		
Sudden	Gains		11	experienced	by	patients	in	both	treatment	groups	was	1	(MANTRA	range	=	0	to	8;	SSCM	1	 range	=	0	to	5).	A	graph	showing	the	frequency	distribution	of	the	number	of	SGs	can	be	2	 found	in	the	online	supplement.	3	 The	median	change	in	weight	during	periods	defined	as	a	SG	was	0.81kg/week	4	 (range	=	0.47	to	6.61):	0.83kg/week	(range	=	0.50	to	6.61)	for	MANTRA	and	5	 0.80kg/week	(range	=	0.47	to	1.52)	for	SSCM.	This	was	equal	to	a	BMI	increase	of	0.32	6	 kg/m2	per	week	for	MANTRA	(range	=	0.19	to	2.43),	and	0.31	kg/m2	per	week	for	SSCM	7	 (range	=	0.19	to	0.77).	The	median	length	of	time	between	baseline	and	a	patient’s	first	8	 SG	was	107	days	(range	=	29	to	259)	for	MANTRA,	and	91.5	days	(range	=	27	to	292)	for	9	 SSCM.	The	majority	(73.5%)	of	SGs	were	experienced	during	the	first	6	months	of	10	 treatment,	and	94.1%	occurred	within	the	fist	9	months.	11	 SGs	occurred	most	often	after	session	12	for	MANTA	and	after	sessions	5,	9,	or	12	 12	for	SSCM	(see	figure	2).	Three	participants	experienced	a	SG	after	their	first	session	13	 with	a	close	other	(session	CO1).		14	 	15	 Characteristics	of	Individuals	Experiencing	Sudden	Gains	16	 Those	who	had	at	least	one	SG	had	spent	significantly	more	years	in	education	17	 (median=17.0,	range=12.0-20.0)	than	those	not	experiencing	SGs	(median=15.0,	18	 range=8.0-20.0),	U	=	453.00,	p	<	.007**,	r	=	0.31.	Those	who	had	at	least	one	SG	19	 had	a	significantly	lower	DASS-21	score	at	baseline	(mean=27.4,	SD=10.6)	compared	to	20	 those	not	experiencing	SGs	(mean=32.9,	SD=11.3),	t(85)	=	2.27,	p	<	.026*,	d	=		0.50.,	21	 95%	CI	[0.67,	10.19].	Comparing	demographic	and	clinical	characteristics	of	those	who	22	 did	and	did	not	experience	SGs	revealed	no	other	significant	differences	(see	table	2,	23	 online	supplement).	24	 	25	
		
Sudden	Gains		12	Summary	Statistics	of	Outcome	Measures	1	 Table	3	shows	the	mean	BMI	and	EDE	global	scores,	as	measured	at	baseline	and	6,	12	2	 and	24	months	post-randomization	and	all	other	outcomes	measured	at	baseline	and	24	3	 months	post-randomization,	separately	for	individuals	who	did	and	did	not	experience	4	 SGs.		5	
	6	 Associations	Between	The	Proportion	of	Sudden	Gains	and	Long-Term	Treatment	7	 Outcomes	8	 The	proportion	of	SGs	was	a	significant	positive	predictor	of	BMI	change	between	9	 baseline	(0	months)	and	6,	12	and	24	months	post-randomization,	with	large	sizes	of	10	 effect	(table	4).	Our	model	did	not	explain	a	significant	amount	of	the	variance	in	the	11	 change	in	any	other	outcome	measures.	12	 	13	 Associations	Between	The	Number	of	Days	to	a	Patient’s	First	Sudden	Gain	and	Long-14	 Term	Treatment	Outcomes	15	 The	number	of	days	between	randomization	and	a	patient’s	first	SG	was	a	significant	16	 negative	predictor	of	BMI	change	between	baseline	(0	months)	and	6	and	12	months	17	 post-randomization,	with	moderate	sizes	of	effect.	However,	the	number	of	days	18	 between	randomization	and	a	patient’s	first	SG	was	not	a	significant	predictor	of	BMI	19	 change	between	baseline	and	24	months	post-randomization	(table	5).	The	number	of	20	 days	between	randomization	and	a	patient’s	first	SG	was	not	a	significant	predictor	of	21	 change	in	any	of	the	MOSAIC	trial	secondary	outcomes.		It	should	also	be	noted	that	22	 there	was	not	a	significant	correlation	between	the	proportion	of	SGs	and	the	number	of	23	 days	to	a	patient’s	first	SG	(p<0.13).	24	 	25	
		
Sudden	Gains		13	DISCUSSION	1	 This	study	was	the	first	to	define	and	operationalize	SGs	in	the	context	of	AN.	We	found	2	 that	61.8%	of	patients	experienced	at	least	one	SG	in	BMI	during	treatment.	As	3	 hypothesized,	a	larger	proportion	of	SGs	predicted	larger	increases	in	BMI	between	4	 baseline	and	6,	12	and	24	months	post-randomization.	Amongst	those	experiencing	at	5	 least	one	SG	during	treatment,	fewer	days	between	randomization	and	a	patient’s	first	6	 SG	predicted	a	larger	increase	in	BMI	between	baseline	and	both	6	and	12	months	post-7	 randomization.		8	 Despite	including	an	additional	criterion	of	suddenness,	the	percentage	of	9	 patients	experiencing	SGs	in	the	current	study	is	somewhat	larger	than	the	40-50%	that	10	 has	previously	been	reported	during	psychological	treatment	for	anxiety	and	11	 depression	(Aderka	et	al.,	2012).	This	may	be	due	to	differences	in	outcome	measures	12	 used	to	define	SGs.	Alternatively;	it	may	be	that	the	criterion	of	absolute	magnitude	13	 used	in	this	study	is	more	lenient	than	previous	definitions.	The	present	study	required	14	 an	average	between-session	gain	of	0.183kg/m2	per	week.	It	could	be	argued	that	this	is	15	 not	a	‘large’	increase	in	weight,	and	therefore	does	not	adhere	to	the	criterion	of	‘large	16	 absolute	magnitude’.	However,	substantial	weight	gain	does	not	typically	occur	over	17	 short	periods	of	time,	and	rapid	weight	gain	can	be	dangerous,	especially	in	the	context	18	 of	AN	(Utzinger	et	al.,	2016).	We	therefore	adapted	the	SG	criteria	in	order	to	use	BMI	as	19	 the	outcome	variable,	ensuring	that	we	were	adhering	to	NICE	guidelines	and	not	20	 requiring	a	weight	increase	that	was	dangerous	or	unrealistic.	21	 Compared	to	those	experiencing	no	SGs,	individuals	who	experienced	at	least	22	 one	SG	had	spent	significantly	longer	in	education,	and	had	a	significantly	lower	DASS-23	 21	total	score	at	baseline.	The	reasons	for	the	association	with	education	are	unclear,	24	 however	lower	depression	scores	have	previously	been	associated	with	more	favorable	25	
		
Sudden	Gains		14	treatment	outcomes	in	ED	treatment	(Wild	et	al.,	2016;	Vall	&	Wade,	2015).	This	study	1	 therefore	supports	these	findings,	suggesting	that	lower	depressions	scores	are	2	 associated	with	better	treatment	outcomes	during	the	outpatient	treatment	of	AN.	3	 There	were	no	other	significant	differences	between	those	who	did	and	did	not	4	 experience	SGs	during	treatment,	suggesting	that	other	demographic	and	clinical	5	 characteristics	cannot	be	used	to	reliably	differentiate	between	individuals	who	do	and	6	 do	not	experience	SGs.		7	 As	hypothesized,	a	larger	proportion	of	SGs	predicted	larger	increases	in	BMI	8	 between	baseline	and	6,	12	and	24	months	post-randomization.	Importantly,	there	were	9	 no	differences	in	BMI	at	baseline	between	those	who	did	and	did	not	experience	SGs,	10	 suggesting	that	those	experiencing	SGs	did	not	have	a	lower	BMI	at	baseline	and	then	11	 regress	towards	the	mean,	as	has	been	previously	suggested	(Konig,	Karl,	Rosner,	&	12	 Butollo,	2014).	However,	it	may	not	be	surprising	that	individuals	who	experienced	13	 more	SGs	in	BMI	during	treatment	had	larger	increases	in	BMI	between	baseline	and	14	 follow-up,	as	SGs	and	outcomes	were	both	measured	from	baseline,	and	therefore	15	 covered	the	same	time	period.	Nevertheless,	our	results	are	clinically	useful,	as	they	16	 provide	insight	into	the	process	of	change	during	the	treatment	of	AN,	and	suggest	that	17	 change	in	BMI	during	AN	treatment	often	occurs	suddenly	between	treatment	sessions.	18	 Furthermore,	our	findings	suggest	that	the	SGs	in	BMI	that	are	experienced	during	19	 treatment	are	maintained	at	follow-up	and	are	therefore	preferable	during	treatment.	20	 SGs	most	often	occurred	during	the	middle	phases	of	treatment,	a	time	when	21	 therapists	typically	work	on	eliciting	change.	This	was	especially	true	for	MANTRA	22	 patients,	suggesting	that	there	may	be	something	specific	about	these	middle	sessions,	23	 which	elicit	SGs.	The	focus	on	clinical	formulation	and	the	creation	of	treatment	plans	24	 may	be	responsible	for	these	SGs	in	BMI.	These	findings	regarding	the	timings	of	SGs	25	
		
Sudden	Gains		15	contradict	some	previous	suggestions	that	SGs	most	often	occur	early	during	treatment.	1	 Within	the	present	study,	when	defining	SGs,	there	was	no	distinction	made	between	2	 those	that	occurred	early	and	later	during	treatment,	due	to	the	considerable	variation	3	 in	the	timing	of	SGs	and	the	controversy	regarding	the	definition	of	‘early’.	This	4	 variation	in	timing	of	SGs	within	the	present	sample	may	be	due	to	the	fact	that,	5	 although	treatments	were	manualized,	there	was	considerable	flexibility	regarding	the	6	 specific	content	of	each	therapy	session.	Thus,	it	is	possible	that	certain	topics	covered	7	 during	treatment	coincided	with	SGs,	but	were	covered	in	different	sessions	for	8	 different	patients.	Alternatively,	it	is	possible	that	factors	such	as	motivation	to	change,	9	 or	therapeutic	alliance	were	associated	with	SGs,	rather	than	the	content	of	treatment	10	 sessions.		11	 In	line	with	previous	findings	(Lutz	et	al.,	2007),	amongst	those	experiencing	at	12	 least	one	SG	during	treatment,	fewer	days	between	randomization	and	a	patient’s	first	13	 SG	predicted	larger	increases	in	BMI	between	baseline	and	both	6	and	12	months	post-14	 randomization.	It	may	consequently	be	suggested	that	individuals	who	experience	SGs	15	 earlier	during	treatment	have	better	treatment	outcomes.	This	association	does	not	16	 appear	to	be	mediated	by	the	total	number	of	SGs	experienced	during	treatment,	as	17	 there	was	no	significant	correlation	between	proportion	of	SGs	and	the	number	of	days	18	 between	randomization	and	patients’	first	SG.	Our	findings	did	not	support	the	19	 hypothesis	that	the	number	of	days	between	randomization	and	a	patient’s	first	SG	20	 would	be	predictive	of	BMI	change	between	baseline	and	24	months	post-21	 randomization.		22	 	23	 Limitations	and	Conclusions	24	 This	study	has	several	limitations.	Firstly,	almost	30%	of	MOSAIC	patient	files	were	25	
		
Sudden	Gains		16	missing.	This	was	partly	due	to	patients	dropping	out	of	the	study	prior	to	the	start	of	1	 treatment	and	therapist	non-compliance	with	record	keeping.	However,	it	is	also	2	 possible	that	files	may	have	been	missing	for	reasons,	such	as	patients	not	attending	3	 therapy	sessions.	Similarly,	there	was	a	large	variation	in	the	number	of	weight	4	 measures	recorded	for	each	participant,	and	lack	of	consistency	in	the	timing	of	these	5	 recordings,	making	it	difficult	to	precisely	investigate	the	trajectory	of	weight	change.	6	 This	complicated	the	calculations	of	SGs,	requiring	us	to	use	the	proportion	of	SGs	7	 rather	than	the	raw	number	of	SGs,	making	interpretation	of	these	findings	more	8	 challenging.		9	 The	MOSAIC	study	was	not	designed	to	investigate	SGs	and	the	data	was	10	 therefore	not	optimal	for	the	current	study.	Firstly,	weight	was	the	only	variable	to	be	11	 measured	at	each	session,	limiting	our	choice	as	to	how	to	define	SGs.	In	addition,	the	12	 number	of	days	between	weight	measures	varied	considerably.	Large	gaps	between	13	 measurements	make	it	impossible	to	determine	the	true	suddenness	of	SGs.	Other	14	 possible	reasons	for	missing	weight	data	include	the	fact	that	there	was	a	large	15	 variability	in	the	number	of	treatment	sessions	attended	by	patients	during	the	MOSAIC	16	 trial	(Schmidt	et	al.,	2015);	and	patients	sometimes	refused	to	be	weighed.	It	is	likely	17	 that	this	is	not	a	random	subsample	of	patients,	further	highlighting	the	challenges	of	18	 missing	data.	We	encourage	future	researchers	to	more	rigorously	collect	session-by-19	 session	data	for	multiple	variables	in	order	to	investigate	SGs	in	BMI	and	other,	20	 psychological	symptoms	of	AN.	21	 Despite	these	limitations,	the	present	study	progresses	research	into	the	22	 treatment	of	AN	by	suggesting	that	there	are	SGs	in	BMI	during	treatment,	and	that	23	 these	are	related	to	better	long-term	outcomes.	Further	research	is,	however,	required	24	 to	determine	which	components	of	therapy	most	often	precede	SGs	in	order	to	identify	25	
		
Sudden	Gains		17	aspects	of	therapy	that	are	most	crucial	in	affecting	change.	Future	research	could	also	1	 explore	whether	there	are	SGs	in	psychological	symptoms	of	AN,	and,	if	present,	2	 whether	these	are	related	to	better	outcomes.	This	would	also	allow	comparisons	to	be	3	 made	with	research	into	SGs	in	CHEDS	scores	during	treatment	for	bulimia	nervosa	4	 (Cavallini	&	Spangler,	2013).	5	 In	sum,	the	present	study	was	the	first	to	investigate	SGs	during	the	treatment	of	6	 AN.	Our	findings	provide	support	for	previous	research	in	other	psychiatric	disorders	7	 suggesting	that	SGs	are	associated	with	better	treatment	outcomes	(Aderka	et	al.,	2012)	8	 and	suggest	that	patients	show	SGs	in	weight	during	treatment.	Future	research	9	 investigating	factors	that	precede	these	SGs	may	help	researchers	to	identify	the	10	 components	of	therapy	that	are	most	important	in	affecting	change	in	AN,	and	thereby	11	 contributing	to	the	development	of	more	effective	treatments.		12	 	13	 	14	 	15	 	16	 	17	 	18	 	19	 	20	 	21	 	22	 	23	 	24	 	25	
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FIGURE	CAPTIONS	1	
Figure	1.	Diagram	illustrating	the	availability	of	weight	data	at	various	assessment	time	2	
points.		3	
Figure	2.	Frequency	distribution	of	the	session	number	preceding	all	sudden	gains.	CO1	=	4	
first	session	with	a	close	other.	5	
Online	Supplement	Figure.	Frequency	distribution	of	the	number	of	sudden	gains	per	6	
patient.		7	
		8	
			 Missing	Sample	 	 Present	Sample	 Test	
N	 	 N	 	Demographic	details	 	 	 	 	 								Age,	years	(median	[range])	 53	 	25	(18-49)	 89	 23	(18-52)	 U	=	2219.50,	p	=	.56								Men:Women	(n)	 53	 1:52	 89	 2:87	 FET,	p	=	1.00	(2-sided)								Years	in	education	(median	[range])	 47	 16	(12-20)	 79	 16	(8-20)	 U	=	1787.00,	p	=	.88									In	relationship	(n	[%])	 50	 15	(30.0)	 88	 35	(39.8)	 χ2(1)	=	1.32,	p	=	.25	Clinical	details	 	 	 	 	 								Treatment	group	(SSCM:	MANTRA)	 53	 32:21	 89	 38:51	 χ2(1)	=	4.16,	p	=	.04*								Diagnosis	(n	[%])	 53	 	 89	 	 χ2(2)	=	2.11,	p	=	.35								AN-R	 	 28	(52.8)	 	 37	(41.6)	 								AN-BP	 	 15	(28.3)	 	 27	(30.3)	 								EDNOS	 	 10	(18.9)	 	 25	(28.1)	 								BMI,	kg/m2	(mean	[SD])	 47	 16.6	(1.2)	 87	 16.7	(1.3)	 t(132)	=	0.42,	p	=	.67								Weight,	kg	(mean	[SD])	 48	 44.6	(4.5)	 88	 45.6	(4.9)	 t(134)	=	-1.16	,	p	=	.25								Binge	(median	[range])	 50	 0	(0-20)	 83	 0	(0-40)	 U	=	2067.00,	p	=	.85								Vomit	(median	[range])	 51	 0	(0-20)	 86	 0	(0-40)	 U	=	2138.50,	p	=	.78								Laxative	use	(median	[range])	 50	 0	(0-7)	 86	 0	(0-21)	 U	=	2002.00,	p	=	.47								Age	at	onset,	years	(median	[range])	 48	 16.0	(5.0-43.0)	 86	 16.5	(2.0-44.0)	 U	=	1856.50,	p	=	.33								Illness	duration,	years	(median	[range])	 48	 7.5	(1.0-37.0)	 86	 5.5	(0.5-34.0)	 U	=	1850.00,	p	=	.32								Previous	ED	treatment	(n	[%])	 52	 29	(55.8)	 89	 51	(57.3)	 χ2(1)	=	0.06,	p	=	.80								EDE	(mean	[SD])	 53	 3.4	(1.4)	 89	 3.3	(1.2)	 t(140)	=	0.47,	p	=	.64								DASS-21	(mean	[SD])	 51	 32.2	(15.0)	 87	 29.5	(11.1)	 t(82.23)	=	1.13,	p	=	.26								OCI-R	(mean	[SD])	 51	 25.6	(15.9)	 88	 22.4	(12.2)	 t(84.54)	=	1.26,	p	=	.21								CIA	(mean	[SD])	 51		 33.8	(10.2)	 89	 31.8	(8.0)	 t(139)	=	1.23,	p	=	.21								Current	antidepressant	medication	(n	[%])	 52	 55	(26.9)	 88	 41	(46.6)	 χ2(1)	=	5.31,	p	=	.02*	
Table	1.	
Baseline	Characteristics	of	the	Missing	MOSAIC	sample	and	the	present	sample	
Note.	 *p	<	0.05.	The	Missing	Sample	column	includes	participants	who	were	 in	 the	MOSAIC	sample,	who	were	not	included	within	 the	 present	 sample.	 The	Test	 column	 shows	 results	 of	 t-tests,	Mann-Whitney	U	 tests,	 Chi-Square	tests,	 and	 Fisher’s	 Exact	 Tests	 used	 to	 test	 for	 differences	 between	 the	 two	 groups.	 SSCM	 Specialist	 Supportive	Clinical	Management;	MANTRA	Maudsley	Model	of	Anorexia	Nervosa	Treatment	for	Adults;	AN-R	anorexia	nervosa,	restricting	 type;	 AN-BP	 anorexia	 nervosa,	 binge	 eating/purging	 type;	 EDNOS	 Eating	 Disorder	 Not	 Otherwise	Specified;	BMI	body	mass	index;	EDE	Eating	Disorder	Examination;	DASS-21	Depression	Anxiety	Stress	Scale;	OCI-R	Obsessive	Compulsive	Inventory–Revised;	CIA	Clinical	Impairment	Assessment.		
	 	 SG	 No	SG	 Test		 N	 	 N	 	Demographic	details	 	 	 	 	 								Age,	years	(median	[range])	 55	 24.0	(18.0-45.0)	 34	 23.0	(18.0-52.0)	 U	=	915.00,	p	=	.87								Men:Women	(n)	 55	 0:55	 34	 2:32	 FET,	p	=	.14	(2-sided)								Years	in	education	(median	[range])	 51	 17.0	(12.0-20.0)	 28	 15.0	(8.0-20.0)	 U	=	453.00,	p	=	.007**,	r	=	0.31								In	relationship	(n	[%])	 55	 19.0	(34.5)	 34	 16.0	(47.1)	 χ2(1)	=	1.23,	p	=	.27	Clinical	details	 	 	 	 	 								Treatment	group	(SSCM:MANTRA)	 55	 20:35	 34	 18:16	 χ2(1)	=	2.36,	p	=	.12								Diagnosis	(n	[%])	 55	 	 34	 	 χ2(2)	=	0.13,	p	=	.94								AN-R	 	 23	(41.8)	 	 14	(41.2)	 								AN-BP	 	 16	(29.1)	 	 11	(32.4)	 								EDNOS	 	 16	(29.1)	 	 9	(26.5)	 								BMI,	kg/m2	(mean	[SD])	 55	 16.7	(1.3)	 34	 16.6	(0.9)	 t(87)	=	-0.33,	p	=	.75								Weight,	kg	(mean	[SD])	 54	 45.6	(5.2)	 34	 45.7	(4.4)	 t(86)	=	0.14,	p	=	.89								Binge	(median	[range])	 55	 0.0	(0.0-40.0)	 34	 0.0	(0.0-28.0)	 U	=	906.00,	p	=	.76								Vomit	(median	[range])	 55	 0.0	(0.0-40.0)	 34	 0.0	(0.0-28.0	 U	=	827.50,	p	=	.29								Laxative	use	(median	[range])	 55	 0.0	(0.0-21.0)	 34	 0.0	(0.0-7.0)	 U	=	893.00,	p	=	.54								Age	at	onset	(median	[range])	 52	 17.0	(9.0-44.0)	 33	 16.0	(11.0-34.0)	 U	=	849.00,	p	=	.82								Illness	duration,	years	(median	[range])	 53	 5.0	(0.5-24.0)	 33	 6.0	(1.0-34.0)	 U	=	807.50,	p	=	.55								Previous	ED	treatment	(n	[%])	 55	 31	(56.4)	 34	 20	(58.8)	 χ2(1)	=	0.15,	p	=	.70								EDE	Global	Score	(mean	[SD])	 55	 3.3	(1.2)	 34	 3.2	(1.3)	 t(87)	=	-0.31,	p	=	.76								DASS-21	Total	Score	(mean	[SD])	 54	 27.4	(10.6)	 33	 32.9	(11.3)	 t(85)	=	2.27,	p	=	.026*,	d	=		0.50								OCI-R	Total	Score	(mean	[SD])	 55	 21.7	(12.0)	 33	 23.5	(11.7)	 t(86)	=	0.66,	p	=	.51								CIA	Total	Score	(mean	[SD])	 55	 31.7	(8.5)	 34	 32.1	(7.4)	 t(87)	=	0.24,	p	=	.81		On	antidepressant	medication	(n	[%])	 55	 24	(43.6)	 33	 17	(51.5)	 χ2(1)	=	0.52,	p	=	.48	
Table	2.	
Baseline	Characteristics	of	participants	with	and	without	sudden	gains	
Note.	*p	<	0.05,	**p	<	0.01.	The	SG	column	includes	participants	experiencing	≥	1	sudden	gains	(SGs).	The	No	SG	column	includes	participants	who	did	not	have	any	SGs.	The	Test	column	shows	results	of	t-tests,	Mann-Whitney	U	tests,	Chi-Square	tests,	and	Fisher’s	Exact	Tests	used	to	test	for	differences	between	the	two	groups.	SSCM	Specialist	Supportive	Clinical	 Management;	MANTRA	Maudsley	Model	 of	 Anorexia	 Nervosa	 Treatment	 for	 Adults;	 AN-R	 anorexia	 nervosa,	restricting	type;	AN-BP	anorexia	nervosa,	binge	eating/purging	type;	EDNOS	Eating	Disorder	Not	Otherwise	Specified;	BMI	body	mass	 index;	 EDE	Eating	Disorder	 Examination;	DASS-21	Depression	Anxiety	 Stress	 Scale;	OCI-R	Obsessive	Compulsive	Inventory–Revised;	CIA	Clinical	Impairment	Assessment;	FET	Fisher’s	Exact	Test.			
	
Measure	 SG	 No	SG	
N	 Mean	(SD)	 N	 Mean	(SD)	BMI	 	 	 	 	Baseline	 55	 16.73	(1.34)	 34	 16.65	(0.87)	6-months	 51	 17.81	(1.51)	 29	 16.44	(1.44)	12-months	 49	 18.72	(2.09)	 27	 16.83	(1.63)	24-months	 48	 18.97	(2.39)	 21	 17.00	(2.03)	EDE	Global	 	 	 	 	Baseline	 55	 3.23	(1.25)	 34	 3.32	(1.25)	6-months	 52	 2.45	(1.38)	 29	 2.54	(1.36)	12-months	 49	 2.16	(1.50)	 26	 2.44	(1.39)	24-months	 48	 2.09	(1.55)	 21	 2.89	(1.47)	EDE	Restraint	 	 	 	 	Baseline	 55	 3.63	(1.49)	 34	 3.75	(1.58)	24-months	 48	 1.58	(1.40)	 21	 2.39	(1.43)	EDE	Shape	Concern	 	 	 	 	Baseline	 55	 3.34	(1.72)	 34	 3.67	(1.59)	24-months	 48	 2.28	(1.77)	 21	 2.83	(1.82)	EDE	Weight	Concern	 	 	 	 	Baseline	 55	 3.14	(1.61)	 34	 3.20	(1.67)	24-months	 48	 2.15	(1.52)	 21	 2.89	(1.47)	EDE	Eating	Concern	 	 	 	 	Baseline	 55	 2.80	(1.26)	 34	 2.67	(1.40)	24-months	 48	 2.58	(1.90)	 21	 3.24	(1.72)	DASS-21	Total	 	 	 	 	Baseline	 54	 30.96	(10.38)	 33	 27.12	(11.94)	24-months	 48	 20.00	(11.80)	 20	 32.73	(13.27)	DASS-21	Depression	 	 	 	 	Baseline	 54	 10.76	(4.88)	 33	 9.44	(5.00)	24-months	 48	 6.69	(5.51)	 20	 11.43	(6.13)	DASS-21	Anxiety	 	 	 	 	Baseline	 54	 7.11	(4.04)	 33	 6.33	(4.66)	24-months	 48	 4.15	(3.54)	 20	 8.70	(4.97)	DASS-21	Stress	 	 	 	 	Baseline	 54	 13.09	(4.09)	 33	 11.42	(4.13)	24-months	 48	 9.17	(4.98)	 20	 12.60	(4.19)	OCI-R	Total	 	 	 	 	Baseline	 55	 24.91	(11.87)	 33	 18.15	(11.79)	24-months	 46	 17.07	(13.47)	 16	 21.81	(13.24)	CIA	Total	 	 	 	 	Baseline	 55	 32.75	(7.98)	 34	 30.35	(8.06)									24	months	 46	 19.65	(11.71)	 20	 27.55	(11.64)	
Table	3.	
Summary	statistics	for	all	outcome	measures	presented	separately	for	
those	who	did	and	did	not	experience	sudden	gains	during	treatment	
Note.	Values	in	the	SG	column	include	only	participants	experiencing	at	least	one	sudden	gain.	Values	in	the	No	SG	column	include	only	participants	who	did	not	have	any	sudden	gains	throughout	treatment.		
	Outcome	Measure	 Regression	Coefficient	 Standard	Error	of	Regression	Coefficient	
Standardised	Regression	Coefficient	
p	 Adjusted	
R2	
BMI	0-6	months		 	11.80	 	2.59	 	0.49	 	<.001**	 	0.20**	0-12	months		 16.25	 3.35	 0.52	 <.001**	 0.21**	0-24	months		 18.72	 4.04	 0.54	 <.001**	 0.20**	EDE	Global	 	 	 	 	 	0-6	months	 -0.27	 3.14	 -0.01	 .94	 0.03	0-12	months	 1.21	 3.58	 0.04	 .74	 -0.03	0-24	months	 -4.57	 3.48	 -0.17	 .19	 -0.02	EDE	Restraint		 -0.92	 4.21	 -0.03	 .83	 -0.06	EDE	Shape	Concern	 1.23	 4.88	 0.03	 .80	 -0.02	EDE	Weight	Concern	 -4.5	 4.46	 -0.13	 .32	 -0.03	EDE	Eating	Concern	 -5.50	 4.17	 -0.17	 .19	 -0.01	DASS-21	Total	 -44.87	 35.51	 -0.16	 .21	 0.06	DASS-21	Depression	 -13.29	 15.58	 -0.11	 .40	 0.07	DASS-21	Anxiety	 -20.68	 11.93	 -0.22	 .09	 0.08	DASS-21	Stress	 -6.08	 13.42	 -0.06	 .65	 -0.04	OCI-R	Total	 -36.32	 40.05	 -0.13	 .37	 -0.06	CIA	Total	 -53.32	 27.28	 -0.26	 .06	 0.03	
Table	4		
Results	of	multiple	linear	regression	analyses	exploring	the	associations	between	the	proportion	
of	sudden	gains	and	long-term	treatment	outcomes	
Note:	**	p	<	0.01.	Unless	otherwise	stated,	dependent	variables	were	measured	as	the	difference	in	symptoms	between	baseline	and	24	months	post-randomization.	
			
Outcome	Measure	 Regression	Coefficient	 Standard	Error	of	Regression	Coefficient	
Standardised	Regression	Coefficient	
p	 Adjusted	
R2	
BMI	0-6	months		 	-0.009	 	0.003	 	-0.38	 	.006**	 	0.19*	0-12	months		 -0.012	 0.004	 -0.39	 .01*	 0.06	0-24	months		 -0.009	 0.005	 -0.29	 .07	 -0.02	EDE	Global	 	 	 	 	 	0-6	months	 0.007	 0.004	 0.24	 .10	 0.03	0-12	months	 0.004	 0.005	 0.14	 .36	 -0.04	0-24	months	 0.009	 0.005	 0.30	 .06	 0.03	EDE	Restraint		 0.009	 0.005	 0.28	 .08	 -0.01	EDE	Shape	Concern	 0.010	 0.006	 0.24	 .13	 -0.01	EDE	Weight	Concern	 0.010	 0.005	 0.29	 .07	 0.04	EDE	Eating	Concern	 0.007	 0.005	 0.22	 .16	 -0.03	DASS-21	Total	 0.031	 0.038	 0.13	 .43	 0.00	DASS-21	Depression	 0.011	 0.017	 0.10	 .52	 0.11	DASS-21	Anxiety	 -0.002	 0.013	 -0.03	 .86	 -0.10	DASS-21	Stress	 0.022	 0.015	 0.23	 .15	 -0.04	OCI-R	Total	 0.067	 0.044	 0.24	 .14	 -0.04	CIA	Total	 0.021	 0.032	 0.10	 .52	 -0.04	
Table	5.	
Results	of	multiple	linear	regression	analyses	exploring	the	associations	between	the	number	
of	days	between	randomisation	and	a	patient’s	first	sudden	gain	and	long-term	treatment	
outcomes.	
	
Note:	**p	<	0.01	*p	<	0.05.	Unless	otherwise	stated,	dependent	variables	were	measured	as	the	difference	in	symptoms	between	baseline	and	24	months	post-randomisation.	
